McKinsey Settles for Nearly $600 Million Over Role in Opioid Crisis
Category: Opioid Crisis
More Info: Defective Drugs
McKinsey & Company, the consultant to blue-chip corporations and governments around the world, has agreed to pay nearly $600 million to settle investigations into its role in helping “turbocharge” opioid sales, a rare instance of it being held publicly accountable for its work with clients.
The firm has reached a $573 million agreement with attorneys general in 47 states, the District of Columbia and five territories, according to a court filing in Massachusetts on Thursday. Separate deals were announced in Washington State, for $13 million, and in West Virginia, for $10 million. Nevada, not party to the agreements, will continue to pursue its opioid investigation, according to the attorney general’s office.
The settlements come after lawsuits unearthed a trove of documents showing how McKinsey worked to drive sales of Purdue Pharma’s OxyContin painkiller amid an opioid crisis in the United States that has contributed to the deaths of more than 450,000 people over the past two decades.
See the original article here: https://www.nytimes.com/2021/02/03/business/mckinsey-opioids-settlement.html
About TriMark Legal Funding
TriMark Legal Funding was founded in 2003 and is one of America's foremost legal funding companies. TriMark provides pre settlement funding and settled case funding, sometimes called 'settlement loans', to injured plaintiffs throughout the United States. We offer funding on hundreds of different types of legal claims including personal injury loans, employment litigation funding, work injury accident loans, workers compensation loans, mass tort litigation funding, and multidistrict litigation funding.
We have a sell my structured settlement page for annuitants and we also provide immediate inheritance advance funding for heirs and beneficiaries, as well as legal fee funding for attorneys and law firm financing for legal practices.
|Personal Injury Lawsuits||Other Funding|
Click here to see the original article.